MapLight Therapeutics, Inc. cash flow to debt ratio of -2.38K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

MapLight Therapeutics, Inc.'s free cash flow has decreased 74.17% from $-79.58M last year to $-138.61M, signaling decreasing performance

MapLight Therapeutics, Inc.'s debt to equity ratio is 0.01, which means that the company's assets are healthy financed, signaling financial stability.

MapLight Therapeutics, Inc.'s debt has decreased relative to shareholder equity from 0.06 last year to 0.01 today, signaling strengthened financials

MapLight Therapeutics, Inc. has a net cash position, so leverage is healthy.

MapLight Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

MapLight Therapeutics, Inc. has insufficient data to evaluate this check.

MapLight Therapeutics, Inc.'s short-term assets of $324.67M exceed its short-term liabilities of $16.23M

MapLight Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

MapLight Therapeutics, Inc.'s return on equity of -69.06%, is lower than 15.00%, indicating bad performance

MapLight Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

MapLight Therapeutics, Inc. has insufficient public price history to evaluate earnings stability.

MapLight Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

MapLight Therapeutics, Inc. has negative free cash flow, indicating cash burn

MapLight Therapeutics, Inc.'s yearly earnings has decreased 107.72% since last year from $-77.58M to $-161.15M, signaling decreasing performance

MapLight Therapeutics, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -51.81% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

MapLight Therapeutics, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

MapLight Therapeutics, Inc. has insufficient public price history to evaluate revenue consistency.

MapLight Therapeutics, Inc. has insufficient public price history to evaluate ROE consistency.

MapLight Therapeutics, Inc. has insufficient data to evaluate this check.

MapLight Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

MapLight Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

MapLight Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

MapLight Therapeutics, Inc. has insufficient data to evaluate this check.

MapLight Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

MapLight Therapeutics, Inc. has a price-to-book ratio of 1.38x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

MapLight Therapeutics, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue